Janssen Announces Memorandum of Understanding with University of Tokyo Center of Innovation and Research Institute for Science & Technology, Tokyo University of Science to Identify Opportunities to Develop Innovative Healthcare Solutions

TOKYO, JAPAN, 26 March 2019 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced it has signed a memorandum of understanding (MoU) with The University of Tokyo Center of Innovation and the Research Institute for Science & Technology, Tokyo University of Science to identify and accelerate the discovery, development and commercialization of innovative early-stage, translational pharmaceutical research.

Under the MoU, Janssen Pharmaceutical K.K will work with the universities on opportunities to evaluate and support innovative science that has the potential to address significant unmet needs of patients in Japan and around the world. As part of the MoU, Janssen will offer local deal-making capabilities with the flexibility to adapt deal structures to match opportunities and establish novel collaborations that speed development of medical innovations.

Japan has a strong track record in advancing science, with one of the world’s largest research communities and significant investments that span public and private sectors. These will be critical in the years ahead, as the country looks to address significant health challenges, including a rapidly aging society, which is anticipated to peak in 2040¹. Janssen hopes that through MoUs such as this, it can build on its 40-year legacy in delivering transformational medical innovation to the people of Japan, focusing on better use of new technologies and data science, and providing academic partners with access to the company’s global business, research, development and technical experts.

Christopher Hourigan, President, Janssen Pharmaceutical K.K.; Prof. Yuichi Tei, Deputy Director, Prof. Tomihisa Ikeura, Director, Center of Innovation, The University of Tokyo; Joaquin Duato, Vice Chairman of the Executive Committee of Johnson & Johnson; Prof. Hideaki Takayanagi, Director General, Research Institute for Science & Technology, Prof. Satoru Miyazaki, Dean, Faculty of Pharmaceutical Science, Tokyo University of Science; Rami Suzuki, Head of Medical Affairs, Janssen Pharmaceutical K.K.
The agreement was recognized at a ceremony in Tokyo in the presence of Prof. Tomihisa Ikeura, Director, Center of Innovation, The University of Tokyo; Prof. Hideaki Takayanagi, Director General, Research Institute for Science and Technology, Tokyo University of Science; Joaquin Duato, Vice Chairman of the Executive Committee of Johnson & Johnson; and Christopher Hourigan, President of Janssen Pharmaceutical K.K.

"Janssen recognizes that nearly every part of the drug discovery and development process can be improved with better use of new technology as well as open collaborations. We strongly believe in the potential of connecting academia, government and the medical community, to broaden access to medicines and to drive future innovation," explained Christopher Hourigan. "This partnership will serve as an incubator for solutions that help address some of the world’s greatest health challenges."

The University of Tokyo Center of Innovation (COI) specializes in the maintenance and improvement of health, based on the utilization of medical information. Its “Self-Managing Healthy Society” program works to develop innovative technology to reduce hospitalization and visits to the doctor’s office.

"We are delighted to collaborate on tackling some of the most pressing healthcare challenges that Japan is, and will be, facing," said Prof. Ikeura. "The open innovation model of this MoU presents new opportunities to build close and pioneering networks to streamline much-needed investment and to deliver new healthcare solutions."

The Tokyo University of Science is one of Japan’s most prestigious private universities, known for its expertise in physics, pharmacology, scientific research and data science. It has produced more Master of Science than any other private university in Japan.

"Collecting and driving ‘data science’ will be a key focus of our collaboration to ensure that the most effective treatments are delivered to patients, and that the experience and views of patients are incorporated in our research," said Prof. Takayanagi. "We look forward to creating new solutions by bringing together our expertise and knowledge."

The MoU is a continuation of Johnson & Johnson’s academic-industry collaboration program in Japan, following agreements signed with Osaka University in September 2017, the University of Tokyo Center of Innovation in February 2018, and Kyoto University in July 2018.

**About the Janssen Pharmaceutical Companies of Johnson & Johnson**

At Janssen, we’re creating a future where disease is a thing of the past. We’re the Pharmaceutical Companies of Johnson & Johnson, working tirelessly to make that future a reality for patients everywhere by fighting sickness with science, improving access with ingenuity, and healing hopelessness with heart. We focus on areas of medicine where we can make the biggest difference: Cardiovascular & Metabolism, Immunology, Infectious Diseases & Vaccines, Neuroscience, Oncology, and Pulmonary Hypertension. Learn more at [www.janssen.com/Japan](http://www.janssen.com/Japan).

Janssen Pharmaceutical K.K. is part of the Janssen Pharmaceutical Companies of Johnson & Johnson.
Media Contact
Communication & Public Affairs, Janssen Pharmaceutical K.K.
TEL: 03-4411-5046 | FAX: 03-4411-5050 | E-mail: JP-PR@its.jnj.com

Reference: